Stocksigma LogoStocksigma Logo

Wockhardt Reports Q2 FY27 Financial Results and Novel Antibiotic Portfolio Progress

Wockhardt reported Q2 FY27 revenue of Rs 969 Cr, up 24% YoY, while EBITDA rose 3% YoY to Rs 165 Cr (Rs 201 Cr excluding pre-Zaynich launch expenses)

Wockhardt Reports Q2 FY27 Financial Results and Novel Antibiotic Portfolio Progress

Wockhardt Ltd 路 Press Release 路 02 Nov 2026, 10:30 pm

Wockhardt Reports Q2 FY27 Financial Results and Novel Antibiotic Portfolio Progress Wockhardt reported Q2 FY27 revenue of Rs 969 Cr, up 24% YoY, while EBITDA rose 3% YoY to Rs 165 Cr (Rs 201 Cr excluding pre-Zaynich launch expenses). PAT stood at Rs 73 Cr versus Rs 82 Cr in Q2 FY26. Biotech operations surged 68% YoY to Rs 252 Cr, driven by Emerging Markets growth of 52% YoY to Rs 310 Cr. Key pipeline milestones include US FDA approval for Zaynich, EMA review progression, and the completion of Phase 2/3 trials for Foviscu.

Original exchange filing (PDF)

More announcements from Wockhardt Ltd

All Wockhardt Ltd announcements